Systematic review highlights potential Role of N-Acetylcysteine in Thrombotic Thrombocytopenic Purpura.

A systematic review published in Cureus, a part of Springer Nature, examined the published clinical experience of N-acetylcysteine (NAC) in the management of thrombotic thrombocytopenic purpura (TTP), providing additional insights into the therapeutic applications of the molecule. The review focused on treatment strategies, clinical outcomes, and safety findings reported in patients with refractory or relapsing disease. The review evaluated available clinical experiences to better understand the effectiveness of N-acetylcysteine in this rare haematological disorder.

Review Examined Existing Evidence on N-Acetylcysteine Use

Researchers conducted a systematic review of published articles and identified six studies involving 22 adult patients. In all the reported cases, intravenous N-Acetylcysteine was given as adjunctive therapy alongside plasma exchange, corticosteroids, rituximab and other immunosuppressive therapies.

According to the review, platelet recovery was observed following the initiation of NAC, with improvements in hemolysis markers and neurological symptoms reported in several cases. No serious NAC related adverse events identifies and no death-related TTP progression was reported.

According to Precedence Research, the acetylcysteine market size accounted for USD 2.56 billion in 2025 and is predicted to increase from USD 3.11 billion in 2026 to approximately USD 16.97 billion by 2035, expanding at a CAGR of 20.82% from 2026 to 2035, driven by the increasing prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), bronchitis, asthma, and also the rising incidence of acetaminophen overdose.

The publication of the systematic review reflects continued scientific studies aimed at exploring the potential uses of N-Acetylcysteine across different therapeutic areas. The authors emphasised that the available evidence is derived from case series and remains insufficient to establish efficacy. The review concluded that N-acetylcysteine appears to be a biologically plausible and generally well tolerated adjunctive therapy. The authors highlighted the need for prospective studies to better define optimal dosing, patient selection and therapeutic role of NAC in thrombotic thrombocytopenic purpura.

A recent report by Precedence Research highlights that the rising respiratory disease cases, expanding healthcare access, and ongoing research into new therapeutic applications are driving the N-Acetylcysteine market growth.